Literature DB >> 10208417

Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics.

A Catteau1, W H Harris, C F Xu, E Solomon.   

Abstract

Reduced expression of BRCA1 has been reported in sporadic breast cancer, although the mechanisms underlying this phenomenon remain unclear. Abnormal methylation leading to silencing of tumour suppressor genes has been implicated in tumorigenesis in a wide range of sporadic cancers. Therefore, we sought to determine the frequency of methylation within the BRCA1 promoter region in a large group of sporadic invasive breast (n =96) and ovarian (n = 43) carcinomas using Southern analyses. Overall, methylation was detected in 11% of breast cancer cases and in 5% of ovarian tumours. Methylation of the BRCA1 promoter region was strongly correlated with lack of estrogen and progesterone receptor expression. It is clear from the frequency of abnormal methylation of the BRCA1 promoter region, that this cannot be the sole mechanism mediating the reduced expression of BRCA1 that has previously been reported to occur in the majority of invasive sporadic breast tumours. Nevertheless this study suggests that abnormal methylation of the BRCA1 promoter may be important in tumorigenesis in a subset of sporadic breast and ovarian cancers.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10208417     DOI: 10.1038/sj.onc.1202509

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  88 in total

Review 1.  Epigenetic changes of DNA repair genes in cancer.

Authors:  Christoph Lahtz; Gerd P Pfeifer
Journal:  J Mol Cell Biol       Date:  2011-02       Impact factor: 6.216

Review 2.  Poly(Adenosine diphosphate-ribose) polymerase inhibitors in cancer treatment.

Authors:  Sook Ryun Park; Alice Chen
Journal:  Hematol Oncol Clin North Am       Date:  2012-06       Impact factor: 3.722

Review 3.  Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer.

Authors:  Elena S Ratner; Alan C Sartorelli; Z Ping Lin
Journal:  Curr Opin Oncol       Date:  2012-09       Impact factor: 3.645

4.  Basal-like breast cancer displays distinct patterns of promoter methylation.

Authors:  Ji Shin Lee; Mary Jo Fackler; Jae Hyuk Lee; Chan Choi; Min Ho Park; Jung Han Yoon; Zhe Zhang; Saraswati Sukumar
Journal:  Cancer Biol Ther       Date:  2010-06-18       Impact factor: 4.742

5.  Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells.

Authors:  Michael S Goldberg; Deyin Xing; Yin Ren; Sandra Orsulic; Sangeeta N Bhatia; Phillip A Sharp
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

Review 6.  Translational application of epigenetic alterations: ovarian cancer as a model.

Authors:  Marie E Maradeo; Paul Cairns
Journal:  FEBS Lett       Date:  2011-03-12       Impact factor: 4.124

7.  Cancer-specific methylation in the BRCA1 promoter in sporadic breast tumours.

Authors:  Azhar B Ali; Philip T C Iau; Jen-Hwei Sng
Journal:  Med Oncol       Date:  2010-02-05       Impact factor: 3.064

8.  Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma.

Authors:  Gustavo Baldassarre; Sabrina Battista; Barbara Belletti; Sanjay Thakur; Francesca Pentimalli; Francesco Trapasso; Monica Fedele; Giovanna Pierantoni; Carlo M Croce; Alfredo Fusco
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

9.  53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes.

Authors:  Kathryn P Pennington; Anneka Wickramanayake; Barbara M Norquist; Christopher C Pennil; Rochelle L Garcia; Kathy J Agnew; Toshiyasu Taniguchi; Piri Welcsh; Elizabeth M Swisher
Journal:  Gynecol Oncol       Date:  2012-12-12       Impact factor: 5.482

10.  Clinical significance of epigenetic inactivation of hMLH1 and BRCA1 in Tunisian patients with invasive breast carcinoma.

Authors:  Sondes Karray-Chouayekh; Fatma Trifa; Abdelmajid Khabir; Nouredine Boujelbane; Tahia Sellami-Boudawara; Jamel Daoud; Mounir Frikha; Ali Gargouri; Raja Mokdad-Gargouri
Journal:  J Biomed Biotechnol       Date:  2009-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.